International consensus on allergy immunotherapy

International consensus on allergy immunotherapy

Allergen immunotherapy (AIT) has been used to treat allergicdisease since the early 1900s. Despite numerous clinical trialsand meta-analyses proving AIT efficacious, it remainsunderused and is estimated to be used in less than 10% ofpatients with allergic rhinitis or asthma worldwide. In addition,there are large differences between regions, which are not onlydue to socioeconomic status. There is practically no controversyabout the use of AIT in the treatment of allergic rhinitis andallergic asthma, but for atopic dermatitis or food allergy, theindications for AIT are not well defined. The elaboration of awider consensus is of utmost importance because AIT is the onlytreatment that can change the course of allergic disease bypreventing the development of asthma and new allergensensitizations and by inducing allergen-specific immunetolerance. Safer and more effective AIT strategies are beingcontinuously developed both through elaboration of new allergen preparations and adjuvants and alternate routes ofadministration. A number of guidelines, consensus documents,or both are available on both the international and nationallevels. The international community of allergy specialistsrecognizes the need to develop a comprehensive consensusreport to harmonize, disseminate, and implement the best AITpractice. Consequently, the International Collaboration inAsthma, Allergy and Immunology, formed by the EuropeanAcademy of Allergy and Clinical Immunology; the AmericanAcademy of Allergy, Asthma & Immunology; the AmericanCollege of Allergy, Asthma & Immunology; and the WorldAllergy Organization, has decided to issue an internationalconsensus on AIT.